Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials

Conclusion EPA, especially icosapent ethyl, plus statins had a beneficial effect on reducing the risk of MACEs and mortality in post-PCI patients. Proprotein convertase subtilisin/kexin type-9 inhibitors plus statins were able to reduce the risk of MACEs, but the risk of mortality remained unclear. PROSPERO registration number CRD42018099600.

http://bmjopen.bmj.com/cgi/content/short/13/11/e070827?rss=1

Source: BMJ Open - November 15, 2023 Category: General Medicine Authors: Deng, C.-J., Yan, J., Zheng, Y.-Y., Wu, T.-T., Pan, Y., Hou, X.-G., Wang, S.-F., Sirajidin, S., Aimaitijiang, M., Xie, X. Tags: Open access, Cardiovascular medicine Source Type: research